<?xml version="1.0" encoding="iso-8859-1"?>
<rss version="2.0" xmlns:sy="http://purl.org/rss/1.0/modules/syndication/" xmlns:admin="http://webns.net/mvcb/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
<channel>
<title>Morpholinos for DMD</title>
<link>http://www.scientistsolutions.com/t13491-morpholinos+for+dmd.html</link>
<description>Low doses induced exon 51 skipping Life Science Discussion</description>
<language>en-us</language> 
<managingEditor>sci7feed@sci7.nojunkorherepleasespam.com</managingEditor>
<sy:updatePeriod>hourly</sy:updatePeriod>
<sy:updateFrequency>1</sy:updateFrequency>
<sy:updateBase>2005-05-05T12:00+00:00</sy:updateBase>
<item>
<title>Morpholinos for DMD</title>
<link>http://www.scientistsolutions.com/t13491-morpholinos+for+dmd.html</link>
<description><![CDATA[AVI Biopharma is reporting that their Morpholino drug for Duchenne muscular dystrophy is successfully triggering dose-dependent exon-skipping in the early low-dose phase of their systemic trial.  Doses of 2 and 4 mg/Kg induced exon skipping and higher dosing is ongoing.<br />http://finance.yahoo.com/news/Systemic-Treatment-With-iw-679670786.html?x=0&amp;.v=1]]></description>
<pubDate>Tue, 22 Dec 2009 09:55:07 GMT</pubDate>
</item>
</channel></rss>
